课题基金 / 基金详情

Deciphering the metabolic and tumorigenic functions of STAT1 in mutant KRAS cancer.

Deciphering the metabolic and tumorigenic functions of STAT1 in mutant KRAS cancer.
破译 STAT1 在突变型 KRAS 癌症中的代谢和致瘤功能。
批准号：
444406
负责人：
Koromilas Antonis E
金额：
$67.99万
依托单位：
CIUSSS de Centre-Ouest-de-l'Ile-de-Montral-Jewish General
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2021
资助国家：
加拿大
项目状态：
未结题
起止时间：
2021-04-01 至 2026-04-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=444406&lang=en
关键词：
Anti-Tumor Drugs Gene Expression Kras Oncogene Protein Phosphorylation Sterol And Lipid Metabolism Transcription Factor Stat1 Transgenic Mice Tumor Formation

项目摘要

项目成果

Koromilas Antonis E的其他基金

相似基金

相关文献

中文摘要
翻译
KRAS基因的突变在致命的癌症中被发现，如结直肠癌、肺癌和胰腺癌。突变的KRAS基因产生一种蛋白质，该蛋白质具有增强细胞增殖和促进肿瘤生长的能力。同时，突变的KRAS
英文摘要
Mutations in KRAS gene are found in deadly forms of cancer like colorectal, lung and pancreatic cancers. Mutant KRAS gene produces a protein, which has the capacity to enhance the proliferation of cells and promote tumor growth. Also, mutant KRAS rewires
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
eIF2 phosphatase inhibitors in the treatment of Trastuzumab-resistant breast cancer.
The implication of the adaptive arm of the integrated stress response in KRAS lung cancer.
Mechanisms and therapeutic implications of PKR and eIF2 phosphorylation in HER2 breast tumor suppression.
The function of eIF2alpha phosphorylation in Ras signaling and lung tumorigenesis.
海外基金